Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
Fish and Richardson
Moodys
QuintilesIMS
Farmers Insurance
Cantor Fitzgerald
Colorcon
Citi
Express Scripts

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022255

« Back to Dashboard
NDA 022255 describes VIMPAT, which is a drug marketed by Ucb Inc and is included in three NDAs. It is available from three suppliers. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the VIMPAT profile page.

The generic ingredient in VIMPAT is lacosamide. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lacosamide profile page.

Summary for NDA: 022255

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 022255

Suppliers and Packaging for NDA: 022255

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMPAT
lacosamide
SOLUTION;ORAL 022255 NDA UCB, Inc. 0131-5410 0131-5410-70 465 mL in 1 BOTTLE, PLASTIC (0131-5410-70)
VIMPAT
lacosamide
SOLUTION;ORAL 022255 NDA UCB, Inc. 0131-5410 0131-5410-71 200 mL in 1 BOTTLE, PLASTIC (0131-5410-71)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength10MG/ML
Approval Date:Apr 20, 2010TE:AARLD:Yes
Regulatory Exclusivity Expiration:Aug 29, 2017
Regulatory Exclusivity Use:INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
Regulatory Exclusivity Expiration:Aug 29, 2017
Regulatory Exclusivity Use:LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
Regulatory Exclusivity Expiration:Aug 29, 2017
Regulatory Exclusivity Use:USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

Expired Orange Book Patents for NDA: 022255

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc
VIMPAT
lacosamide
SOLUTION;ORAL022255-001Apr 20, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Farmers Insurance
Citi
Harvard Business School
AstraZeneca
Fuji
McKesson
Accenture
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot